Europäische Union - Slowenisch - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hipofiza in hypothalamic hormoni in analogi - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetil fumarat - multiplo sklerozo, recidivno-nakazila - imunosupresivi - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatične neoplazme - endokrini terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Europäische Union - Slowenisch - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - cepiva - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi deutschland gmbh - remifentanil - prašek za koncentrat za raztopino za injiciranje/infundiranje - remifentanil 1 mg / 1 viala - remifentanil

Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - fluorouracil - raztopina za injiciranje/infundiranje - fluorouracil 50 mg / 1 ml - fluorouracil

Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - fluorouracil - raztopina za injiciranje/infundiranje - fluorouracil 50 mg / 1 ml - fluorouracil

Slowenien - Slowenisch - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

hospira uk ltd - ceftazidim - prašek za raztopino za injiciranje/infundiranje - ceftazidim 1000 mg / 1 viala - ceftazidim